Newsletter | November 7, 2019

11.07.19 -- Cell & Gene Best Of October

 

Hello Cell & Gene readers,

 

I’m happy to bring you October’s most-clicked articles. Enjoy.

 

Erin Harris, editor in chief
Follow me on Twitter

October's Best Featured Editorial
CAR T-Cell Therapies: Current Limitations & Future Opportunities
By Anamika Ghosh, Ph.D., and Dana Gheorghe, Ph.D., DRG Oncology

Novel technologies to address areas left unaddressed by Kymriah and Yescarta have started streaming into the research arena. This article focuses on the barriers to widespread commercial adoption of the currently available CAR T cell therapies, and opportunities for developers of next-generation treatments.

Potential Solutions To Current Pricing Models For Cell And Gene Therapies
By Erin Harris, Editor-In-Chief, Cell & Gene

Curative cell & gene therapies are changing modern medicine as we know it, but are their high price tags fair to the patient?

Building A $1 Billion Gene Therapy Company — In 6 Years
By Rob Wright, Chief Editor, Life Science Leader

Matt Patterson, chairman and CEO of Audentes Therapeutics, shares the experiences that prepared him for building the gene therapy company he cofounded into a publicly traded business valued at nearly $2 billion.

October's Best Industry Insights
Moving Toward A Closed CAR T Cell Manufacturing Process
By Devina Ramsaroop, Steven Loo Yong Kee, Danylo Sirskyj, Calley Hirsch, Elizabeth Csaszar, and Aaron Dulgar Tulloch, GE Healthcare Life Sciences

Challenges to overcome in the CAR T manufacturing process include lengthy production times (11 -  21 days), product variability associated with open handling steps, and high manufacturing costs. Here we examine and evaluate individual CAR T cell unit operations, commercial reagents, and equipment with process closure potential to develop an improved workflow and increased product consistency.

Overcoming The Unique Filling Challenges Of Autologous Therapies
By Herman F. Bozenhardt and Erich H. Bozenhardt, Integrated Project Services (IPS)

Autologous (patient-derived) therapies represent unique challenges to processing. One-patient, single-batch is a radical change from the scale our industry is accustomed to. At this level the filling is more analogous to limited Phase 1 clinical trial materials or even preclinical applications. The logistics and required compliance of manufacturing these personalized therapies is drastically different and presents a combinatorial explosive problem. One aspect of this process where traditional methods fall apart is filling of these therapies.

Moving Forward With Immunotherapies For Cancer
By Barbara Gilmore, Senior Consultant, Transformational Health, Frost & Sullivan

Industry experts joined a panel at Frost & Sullivan's Virtual Think Tank recently to discuss the current state of immunotherapies, implications of research and development occurring today, key challenges, and future approaches to the targeted use of the immune system in cancer treatment. Read their thoughts on immunotherapies and the critical role for the immune system to play, especially in the advanced stages of cancer, since traditional standard-of-care therapies do often work fairly well.

Connect With Cell & Gene:
      Twitter